Cellectar Biosciences, Inc. (CLRB) stock
CLRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.89−0.04 (-3.81%)
Close on Nov 18, 2026Market cap $8.37MP/E –Yield –
Cellectar Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Cellectar Biosciences's free cash flow for the twelve months ending Dec 31, 2024 was -$47.69M. For fiscal 2025 it was -$23.12M. The highest annual figure on record is -$3.38M in fiscal 2010.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$23.12M | – |
| FY2024 | Dec 31, 2024 | -$47.69M | – |
| FY2023 | Dec 31, 2023 | -$33.24M | – |
| FY2022 | Dec 31, 2022 | -$25.45M | – |
| FY2021 | Dec 31, 2021 | -$22.71M | – |
| FY2020 | Dec 31, 2020 | -$14.00M | – |
| FY2019 | Dec 31, 2019 | -$11.72M | – |
| FY2018 | Dec 31, 2018 | -$11.83M | – |
| FY2017 | Dec 31, 2017 | -$11.37M | – |
| FY2016 | Dec 31, 2016 | -$8.35M | – |
| FY2015 | Dec 31, 2015 | -$8.27M | – |
| FY2014 | Dec 31, 2014 | -$8.87M | – |
| FY2013 | Dec 31, 2013 | -$9.30M | – |
| FY2012 | Dec 31, 2012 | -$6.68M | – |
| FY2011 | Dec 31, 2011 | -$6.09M | – |
| FY2010 | Dec 31, 2010 | -$3.38M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.01M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.85M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.97M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.17M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.16M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.38M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.86M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.53M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.83M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.07M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.64M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.43M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.89M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.50M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.08M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.52M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.69M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.55M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.66M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.82M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.13M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.97M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.55M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.19M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.83M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.57M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.92M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.05M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.42M | – |
| Q3 FY2016 | Sep 30, 2016 | -$2.21M | – |
See a number that looks wrong?